The Antiproliferative Effects of Progestins in T47D Breast Cancer Cells Are Tempered by Progestin Induction of the ETS Transcription Factor Elf5

Overview

Journal Mol Endocrinol

Specialties Endocrinology
Molecular Biology

Date 2010 Jun 4

PMID 20519331

Citations 9

Authors

H N Hilton

M Kalyuga

M J Cowley

M C Alles

H J Lee

C E Caldon

K Blazek

W Kaplan

E A Musgrove

R J Daly

M J Naylor

J D Graham

C L Clarke

C J Ormandy

Affiliations

Soon will be listed here.

Abstract

Prolactin and progesterone act together to regulate mammary alveolar development, and both hormones have been implicated in breast cancer initiation and progression. Here we show that Elf5, a prolactin-induced ETS transcription factor that specifies the mammary secretory cell lineage, is also induced by progestins in breast cancer cells via a direct mechanism. To define the transcriptional response to progestin elicited via Elf5, we made an inducible Elf5 short hairpin-RNA knock-down model in T47D breast cancer cells and used it to prevent the progestin-induction of Elf5. Functional analysis of Affymetrix gene expression data using Gene Ontologies and Gene Set Enrichment Analysis showed enhancement of the progestin effects on cell cycle gene expression. Cell proliferation assays showed a more efficacious progestin-induced growth arrest when Elf5 was kept at baseline levels. These results showed that progestin induction of Elf5 expression tempered the antiproliferative effects of progestins in T47D cells, providing a further mechanistic link between prolactin and progestin in the regulation of mammary cell phenotype.

Citing Articles

The Role of Progesterone in Elf5 Activation and Milk Component Synthesis for Cell-Cultured Milk Production in MAC-T Cells.

Kwon H, Jung H, Kim D, Han J, Han S Animals (Basel). 2024; 14(4).

PMID: 38396610 PMC: 10886090. DOI: 10.3390/ani14040642.

CCM signaling complex (CSC) couples both classic and non-classic Progesterone receptor signaling.

Abou-Fadel J, Jiang X, Grajeda B, Padarti A, Ellis C, Flores E Cell Commun Signal. 2022; 20(1):120.

PMID: 35971177 PMC: 9377144. DOI: 10.1186/s12964-022-00926-z.

The glucocorticoid receptor interferes with progesterone receptor-dependent genomic regulation in breast cancer cells.

Ogara M, Rodriguez-Segui S, Marini M, Nacht A, Stortz M, Levi V Nucleic Acids Res. 2019; 47(20):10645-10661.

PMID: 31598691 PMC: 6846950. DOI: 10.1093/nar/gkz857.

The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.

Law A, Lim E, Ormandy C, Gallego-Ortega D Endocr Relat Cancer. 2017; 24(4):R123-R144.

PMID: 28193698 PMC: 5425956. DOI: 10.1530/ERC-16-0404.

Endometrial Cancer-Associated FGF18 Expression Is Reduced by Bazedoxifene in Human Endometrial Stromal Cells In Vitro and in Murine Endometrium.

Flannery C, Fleming A, Choe G, Naqvi H, Zhang M, Sharma A Endocrinology. 2016; 157(10):3699-3708.

PMID: 27267714 PMC: 5045514. DOI: 10.1210/en.2016-1233.

References

Ormandy C, Hall R, Manning D, Robertson J, Blamey R, Kelly P . Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab. 1997; 82(11):3692-9. DOI: 10.1210/jcem.82.11.4361. View

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

Neville M, McFadden T, Forsyth I . Hormonal regulation of mammary differentiation and milk secretion. J Mammary Gland Biol Neoplasia. 2002; 7(1):49-66. DOI: 10.1023/a:1015770423167. View

Musgrove E, Lee C, Sutherland R . Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol. 1991; 11(10):5032-43. PMC: 361499. DOI: 10.1128/mcb.11.10.5032-5043.1991. View

Lange C, Richer J, Horwitz K . Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol. 1999; 13(6):829-36. DOI: 10.1210/mend.13.6.0290. View

Rubino D, Driggers P, Arbit D, Kemp L, Miller B, Coso O . Characterization of Brx, a novel Dbl family member that modulates estrogen receptor action. Oncogene. 1998; 16(19):2513-26. DOI: 10.1038/sj.onc.1201783. View

Boonyaratanakornkit V, McGowan E, Sherman L, Mancini M, Cheskis B, Edwards D . The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2006; 21(2):359-75. DOI: 10.1210/me.2006-0337. View

Binart N, Helloco C, Ormandy C, Barra J, Clement-Lacroix P, Baran N . Rescue of preimplantatory egg development and embryo implantation in prolactin receptor-deficient mice after progesterone administration. Endocrinology. 2000; 141(7):2691-7. DOI: 10.1210/endo.141.7.7568. View

Shyamala G, Yang X, Silberstein G, Barcellos-Hoff M, Dale E . Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc Natl Acad Sci U S A. 1998; 95(2):696-701. PMC: 18483. DOI: 10.1073/pnas.95.2.696. View

10.

Harris J, Stanford P, Sutherland K, Oakes S, Naylor M, Robertson F . Socs2 and elf5 mediate prolactin-induced mammary gland development. Mol Endocrinol. 2006; 20(5):1177-87. DOI: 10.1210/me.2005-0473. View

11.

Caldon C, Lee C, Sutherland R, Musgrove E . Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation. Oncogene. 2007; 27(1):126-38. DOI: 10.1038/sj.onc.1210622. View

12.

Lim R, Halpain S . Regulated association of microtubule-associated protein 2 (MAP2) with Src and Grb2: evidence for MAP2 as a scaffolding protein. J Biol Chem. 2000; 275(27):20578-87. DOI: 10.1074/jbc.M001887200. View

13.

KESTER H, van der Leede B, van der Saag P, van der Burg B . Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J Biol Chem. 1997; 272(26):16637-43. DOI: 10.1074/jbc.272.26.16637. View

14.

Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M . Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 1998; 17(7):2008-18. PMC: 1170546. DOI: 10.1093/emboj/17.7.2008. View

15.

Graves B, Petersen J . Specificity within the ets family of transcription factors. Adv Cancer Res. 1998; 75:1-55. DOI: 10.1016/s0065-230x(08)60738-1. View

16.

Kabotyanski E, Rijnkels M, Freeman-Zadrowski C, Buser A, Edwards D, Rosen J . Lactogenic hormonal induction of long distance interactions between beta-casein gene regulatory elements. J Biol Chem. 2009; 284(34):22815-24. PMC: 2755689. DOI: 10.1074/jbc.M109.032490. View

17.

Choi Y, Chakrabarti R, Escamilla-Hernandez R, Sinha S . Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev Biol. 2009; 329(2):227-41. DOI: 10.1016/j.ydbio.2009.02.032. View

18.

Ormandy C, Camus A, Barra J, Damotte D, Lucas B, Buteau H . Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev. 1997; 11(2):167-78. DOI: 10.1101/gad.11.2.167. View

19.

Thomas R, Ng A, Zhou J, Tymms M, Doppler W, Kola I . The Elf group of Ets-related transcription factors. ELF3 and ELF5. Adv Exp Med Biol. 2000; 480:123-8. DOI: 10.1007/0-306-46832-8_15. View

20.

Zhou J, Chehab R, Tkalcevic J, Naylor M, Harris J, Wilson T . Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation. EMBO J. 2005; 24(3):635-44. PMC: 548648. DOI: 10.1038/sj.emboj.7600538. View